

1  
2 **SARS-CoV-2 viremia precedes an IL6 response in severe COVID-**  
3 **19 patients: results of a longitudinal prospective cohort**  
4  
5

6 **Emilia Roy-Vallejo<sup>1†\*</sup>, Laura Cardenoso<sup>2†</sup>, Ana Triguero-Martínez<sup>3</sup>, Marta Chicot**  
7 **Llano<sup>4</sup>, Nelly Zurita<sup>2</sup>, Elena Ávalos<sup>5</sup>, Ana Barrios<sup>1</sup>, Julia Hernando<sup>6</sup>, Javier Ortiz<sup>7</sup>,**  
8 **Sebastián C. Rodríguez-García<sup>3</sup>, Marianela Ciudad Sañudo<sup>1</sup>, Celeste Marcos<sup>5</sup>, Elena**  
9 **García Castillo<sup>5</sup>, Leticia Fontán García-Rodrigo<sup>2</sup>, Begoña González<sup>4</sup>, Rosa Méndez<sup>6</sup>,**  
10 **Isabel Iturrate<sup>7</sup>, Ancor Sanz-García<sup>8</sup>, Almudena Villa<sup>1</sup>, Ana Sánchez Azofra<sup>5</sup>, Begoña**  
11 **Quicios<sup>4</sup>, David Arribas<sup>6</sup>, Jesús Álvarez Rodríguez<sup>1</sup>, Pablo Patiño<sup>4</sup>, Marina Trigueros<sup>4</sup>,**  
12 **Miren Uriarte<sup>3</sup>, Alexandra Martín-Ramírez<sup>2</sup>, Cristina Arévalo Román<sup>1</sup>, José María**  
13 **Galván-Román<sup>1</sup>, Rosario García-Vicuña<sup>3</sup>, Julio Ancochea<sup>5</sup>, Cecilia Muñoz Calleja<sup>9</sup>,**  
14 **Elena Fernández-Ruiz<sup>10</sup>, Rafael de la Cámara<sup>7</sup>, Carmen Suárez Fernández<sup>1</sup>, Isidoro**  
15 **González Álvaro<sup>3§</sup>, Diego A. Rodríguez Serrano<sup>4,11§</sup> on behalf of the PREDINMUN-**  
16 **COVID Group**  
17

18 <sup>1</sup>Internal Medicine Department, Hospital Universitario La Princesa, Madrid, Spain

19 <sup>2</sup>Microbiology Department, Hospital Universitario La Princesa, Madrid, Spain

20 <sup>3</sup>Rheumatology Department, Hospital Universitario La Princesa, Madrid, Spain

21 <sup>4</sup>Intensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain

22 <sup>5</sup>Pneumology Department, Hospital Universitario La Princesa, Madrid, Spain

23 <sup>6</sup>Anesthesiology Department, Hospital Universitario La Princesa, Madrid, Spain

24 <sup>7</sup>Hematology Department, Hospital Universitario La Princesa, Madrid, Spain

25 <sup>8</sup>Methodology Unit. Health Research Institute. Hospital Universitario La Princesa, IIS-IP,  
26 Madrid, Spain

27 <sup>9</sup>Immunology Department, Hospital Universitario La Princesa, Madrid, Spain

28 <sup>10</sup>Molecular Biology Unit, Hospital Universitario La Princesa, Madrid, Spain

29 <sup>11</sup>Currently working at: Intensive Care Unit, Hospital Universitario Príncipe de Asturias,  
30 Alcalá de Henares, Spain

31  
32 <sup>†</sup>These authors have contributed equally to this work and share first authorship

33 <sup>&</sup> These authors have contributed equally to this work and share senior authorship  
34

35 **\* Correspondence:**

36 Emilia Roy Vallejo

37 [eroyvallejo@gmail.com](mailto:eroyvallejo@gmail.com)  
38

39 **Number of words:** 3619 words

40 **Number of figures and tables:** 4  
41  
42

43 **Keywords:** SARS-CoV-2, viremia, Interleukin 6, prognosis, COVID-19  
44  
45  
46  
47  
48  
49  
50

51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101

**Abstract**

*Background:*

Interleukin 6 (IL6) levels and SARS-CoV-2 viremia have been correlated with COVID-19 severity. The association over time between them has not been assessed in a prospective cohort. Our aim was to evaluate the relationship between SARS-CoV-2 viremia and time evolution of IL6 levels in a COVID-19 prospective cohort.

*Methods:*

Secondary analysis from a prospective cohort including COVID-19 hospitalized patients from Hospital Universitario La Princesa between November 2020 and January 2021. Serial plasma samples were collected from admission until discharge. Viral load was quantified by Real-Time Polymerase Chain Reaction and IL6 levels with an enzyme immunoassay. To represent the evolution over time of both variables we used the graphic command *twoway* of Stata.

*Results:*

A total of 57 patients were recruited, with median age of 63 years (IQR [53-81]), 61.4% male and 68.4% caucasian. The peak of viremia appeared shortly after symptom onset in patients with persistent viremia (more than 1 sample with  $>1.3 \log_{10}$  copies/ml) and also in those with at least one IL6 $>30$  pg/ml, followed by a progressive increase in IL6 around 10 days later. Persistent viremia in the first week of hospitalization was associated with higher levels of IL6. Both IL6 and SARS-CoV-2 viral load were higher in males, with a quicker increase with age.

*Conclusions:*

In those patients with worse outcomes, an early peak of SARS-CoV-2 viral load precedes an increase in IL6 levels. Monitoring SARS-CoV-2 viral load during the first week after symptom onset may be helpful to predict disease severity in COVID-19 patients.

102

## 103 **1 Introduction**

104

105 One of the most feared complications of the disease caused by the coronavirus SARS-CoV-2  
106 (COVID-19), is the development of an Acute Respiratory Distress Syndrome (ARDS), which  
107 can affect 15.6-31% of patients [1]. Siddiqui and Mehra [2] proposed that ARDS is part of  
108 the final stage of the disease, in which clinical features are mainly the consequence of the  
109 host hyperinflammatory response and a cytokine storm; whereas the stage I (early infection)  
110 is mainly caused by viral replication and the early immune response. However, to the best of  
111 our knowledge, this proposal has not been validated.

112

113 Since the outbreak of the COVID-19 pandemic, many efforts have been made to find early  
114 risk factors and biomarkers able to predict the evolution towards the cytokine storm. In this  
115 sense, older age, obesity and comorbidities such as hypertension, diabetes and coronary heart  
116 disease have been associated with higher risk of death [3,4]. On the other hand, increased  
117 levels of C reactive protein (CRP), lactate dehydrogenase (LDH) and D-dimer, among others,  
118 have been shown to be related to the development of ARDS and mortality [3,5,6].

119

120 In this context, Interleukin 6 (IL6) has been described as one of the most useful biomarkers  
121 [7]. In a previous work, we showed that IL6 could be a severity biomarker but also a guide to  
122 select COVID-19 patients who could benefit from treatment with tocilizumab, an inhibitor of  
123 the IL6 receptor [8]. Another important biomarker is the presence of SARS-CoV-2 RNA in  
124 peripheral blood (viremia), which has been associated with disease severity and a  
125 hyperinflammatory state [9,10]. Saji et al.[11] showed that the combination of SpO<sub>2</sub>/FiO<sub>2</sub>,  
126 IL6 and the presence of SARS-CoV-2 viremia at admission had the highest accuracy to  
127 predict fatal outcomes. Bermejo et al. [12] and Myhre et al.[13] found that the presence of  
128 SARS-CoV-2 viremia at admission correlated with increased levels of IL6, CRP and ferritin.  
129 In addition, a proteomic analysis showed that the expression of viral response and  
130 interferon/monocytic pathway proteins such as IL6 and one of its regulators, the  
131 Nicotinamide phosphoribosyl transferase (NAMPT), were upregulated in patients with  
132 quantifiable SARS-CoV-2 viremia at admission, compared to those with undetectable  
133 viremia [14].

134

135 In a previous study of our group, we found that viremia was associated with Intensive Care  
136 Unit (ICU) admission and in-hospital death, and it was a better biomarker than IL6 [10]. In  
137 this regard, since SARS-CoV-2 infection is involved in triggering IL6 expression, viremia as  
138 an indicator of the systemic viral shedding, could be related with the IL6 response and be  
139 useful as an early biomarker (phase of viral response). Nevertheless, the factors determining  
140 an IL6 increase in COVID-19 patients have not been well established yet and the association  
141 over time between SARS-CoV-2 viremia and IL6, has not been assessed in a prospective  
142 cohort with serial samples.

143

144 Considering our previous results, the aim of this study was to evaluate the relationship  
145 between the presence of SARS-CoV-2 viremia and the time evolution and IL6 levels in a  
146 prospective cohort of COVID-19 hospitalized patients.

147

## 148 **2 Materials and Methods**

149

### 150 **2.1 Study design, population and data collection**

151 This work is a secondary analysis of samples from a prospective observational cohort  
152 assembled to validate the predictive value of SARS-CoV-2 viremia (ongoing manuscript).

153 The study included patients hospitalized for COVID-19 in Hospital Universitario La Princesa  
154 (HUP) between November 1st 2020 and January 15th 2021.

155

156 The inclusion criteria were: a) positive Real-Time Reverse Transcription Polymerase Chain  
157 Reaction (rRT-PCR) for SARS-CoV-2 in nasopharyngeal and throat swabs at most 48 hours  
158 prior to hospitalization; b) acceptance to participate in the study and oral or written consent;  
159 c) age older than 18 years. The exclusion criteria were: a) patients without an initial viremia  
160 determination in the first 24-36 hours after admission; b) patients unlikely to be followed-up  
161 because they were candidates to be transferred to other health facilities.

162

163 Clinical, laboratory and therapeutic data were collected from electronic clinical records and  
164 included in an anonymized database. Baseline clinical and laboratory data are to those  
165 obtained at admission day.

166

167 The need for hospitalization was decided by the physicians at the emergency room based on  
168 clinical criteria, without the intervention of the research team. Patient's treatment and  
169 management was decided by each attending physician based on the hospital protocols and  
170 their clinical judgment. Attending physicians were blind to the viremia results.

171

## 172 **2.2 Sample size**

173 The sample size was estimated in 49 patients to validate the primary objective of the study  
174 "SARS-CoV-2 viremia as a biomarker of disease severity" (ongoing manuscript) based on  
175 the results of our previous retrospective studies [10,15].

176

## 177 **2.3 Sample collection**

178 Serial plasma and serum samples were collected from admission until discharge. In the first  
179 week, samples were collected every 48 hours, with the first sample in the first 24-36h.  
180 Thereafter, samples were collected twice a week. All samples were frozen at -80 °C and  
181 stored in the Microbiology Department facilities.

182

## 183 **2.4 SARS-CoV-2 RNA extraction and detection**

184 Firstly, a nucleic acid extraction of samples was performed by the automatic eMAG®  
185 Nucleic Acid Extraction System (Biomerieux, France). Detection of viremia was performed  
186 with rRT-PCR using TaqPath™ COVID-19 CE81 IVD RT-PCR Kit (Thermo Fisher  
187 Scientific, USA [TFS]), according to the manufacturer's instructions, by a QuantStudio™ 5  
188 Real Time PCR System (Applied Biosystems, USA). Amplification curves were analyzed  
189 with QuantStudio™ Design and Analysis software version 2.4.3 (Applied Biosystems, USA)  
190 and interpreted by a clinical microbiologist. To increase sensitivity, two wells were used for  
191 each sample. Two positive controls (one of 20,000 copies and another of 200 copies) and two  
192 negative controls were added in each run in duplicate.

193

## 194 **2.5 Quantification of viral load**

195 A standard curve was established using a positive control with a known concentration  
196 (TaqPath Positive Control from TaqPath™ COVID-19 Control Kit) of 10,000 copies/μl of the  
197 SARS-CoV-2 genomic regions targeted by the TFS assay. Ten-fold serial dilutions of the  
198 positive control were made up to 1 copy. Nine wells of each of the concentrations and of the  
199 negative control were added to the run. The rRT-PCR was performed by QuantStudio™ 5  
200 Real Time PCR System and a standard curve was obtained plotting DNA concentration  
201 against cycle threshold (Ct) values. The amplification curves were analyzed with  
202 QuantStudio™ Design and Analysis software version 2.4.3 (Applied Biosystems, USA). The  
203 results of the nine wells with 1 copy were omitted because they were widely dispersed.

204 Viral load was calculated from Ct values using the standard curve as reference and was  
205 expressed as copies/ml and the logarithm with base 10 (log<sub>10</sub>). Due to the variability and lack  
206 of accuracy obtained with the lower levels of SARS-CoV-2 viremia, only viremias >1.3  
207 log<sub>10</sub> (20 copies/ml) were considered quantifiable.

208

## 209 **2.6 IL-6 measurement**

210 Serum samples collected in the same extraction as the plasma used for SARS-CoV-2 viremia  
211 determinations were used to assess IL6 levels. IL6 levels were retrospectively quantified in  
212 triplicate with the Human IL6 DuoSet enzyme-immunoassay from R&D Systems Europe Ltd  
213 (Abingdon, UK), following the manufacturer's instructions.

214

## 215 **2.7 Variables**

216 For analysis using viremia as a quantitative variable, all values were used. However, to define  
217 viremia as categorical, positive viremia was considered when values were higher than 1.3  
218 log<sub>10</sub> (namely 32 copies/ml, which was the threshold for quantifiable viremia) and negative  
219 when values were below this threshold. Persistent viremia was defined as more than one  
220 positive viremia in the first week of hospitalization.

221 Two different variables were used to evaluate IL6 levels: a) a quantitative variable defined as  
222 IL6 concentration, expressed in pg/ml, b) a dichotomic variable, which considered levels of  
223 IL6 as high when at least one IL6 determination was higher than 30 pg/ml or low if all  
224 determinations were below 30 pg/ml. This threshold was based on our previous study, where  
225 we showed that IL6>30 pg/ml was associated with poor respiratory outcomes [8]. The  
226 average levels of IL6 and viral load were defined as the arithmetic mean of all their  
227 determinations in each patient.

228

## 229 **2.8 Statistical analysis**

230 We used Stata 14.0 for Windows (Stata Corp LP, College Station, TX, USA) for all the  
231 analysis described below. Quantitative variables were represented as median and Interquartile  
232 Range (IQR), and the Mann Whitney or Kruskal Wallis tests were used to assess significant  
233 differences, since all quantitative variables followed a non-normal distribution. Qualitative  
234 variables were described as counts and proportions and Chi square or Fisher's exact test was  
235 used for comparisons.

236 In order to comparatively show levels of IL6 and viral load through the two first weeks of  
237 follow-up, we used as time variable the number of days from the beginning of symptoms to  
238 collection of each sample. To represent the mean evolution over time of both variables we  
239 used the graphic command *twoway* from Stata with the option fractional polynomial  
240 prediction with 95% confidence interval (CI). Since it is well known that blockade of IL6  
241 receptor with tocilizumab can result in an increase of IL6 serum levels [16], we decided to  
242 carry forward the last observation before tocilizumab treatment (last observation carried  
243 forward [LOCF] strategy) to replace IL6 values in the remaining visits of the first 2 weeks for  
244 those patients treated with tocilizumab in order to avoid the bias of excluding this important  
245 population (see comparative baseline characteristics in Supplementary Table 1). Furthermore,  
246 we also applied LOCF strategy for those patients who died or were discharged before the 5<sup>th</sup>  
247 visit (14<sup>th</sup> day after admission), in order to obtain a more homogeneous number of  
248 determinations all along the follow-up.

249 To determine which variables were associated with high levels of IL6, we performed a  
250 multivariable logistic regression analysis that was first modelled by adding all the variables

251 with a p value lower than 0.15 in the bivariable analysis. The final model was reached  
252 through backward stepwise removal of variables with p value higher than 0.15.

## 253 **2.9 Ethics**

254 This study was approved by the Research Ethics Committee of Hospital Universitario La  
255 Princesa, Madrid, (register number 4267; 22-10-2020) and it was carried out following the  
256 ethical principles established in the Declaration of Helsinki. As proposed by AEMPS  
257 (Agencia Española de Medicamentos y Productos Sanitarios, The Spanish Agency for  
258 Medicines and Medical Devices), only oral consent was required due to the COVID-19  
259 emergency [17]. However, a written information sheet was also offered to all patients. After  
260 being informed about the study, all included patients (or their representatives) gave informed  
261 consent, which was registered in the electronic clinical chart.

262 This article was written following the STROBE initiative (Strengthening the Reporting of  
263 Observational studies in Epidemiology).

## 264 **3 Results**

### 265 **3.1 Study population and sample characteristics**

266 A total of 57 patients were recruited, with median age of 63 years (IQR 53-81), 61.4% were  
267 male, 68.4% caucasian, and 75.4% had previous comorbidities. The median time from  
268 symptom onset to first sample was 8 days (IQR 4-10). Baseline clinical characteristics  
269 according to IL6 levels are shown in table 1. During patients' hospitalization, 301 serum  
270 samples were collected, with a median number of 3 samples per patient (IQR 2-5).

271 Nine patients were treated with tocilizumab, who on average, showed data suggesting a more  
272 severe disease, although differences did not reach statistical significance (Supplementary  
273 Table 1).

274 Most patients who progressed to a severe disease started this evolution 7 to 14 days after the  
275 symptoms onset. In addition, patients with a more benign course were discharged at the end  
276 of the first week after admission. For clinical consistency, we decided to analyze only the  
277 samples corresponding to the first two weeks of hospitalization, a maximum of 5 samples per  
278 patient. Thus, IL6 levels were measured in 228 samples, with a median of 3.6 pg/ml (IQR 0-  
279 21 pg/ml). Baseline clinical characteristics of patients depending on IL6 status are shown in  
280 table 1. SARS-CoV-2 viremia was determined in 234 samples, with the highest percentage of  
281 positive viremia (36.8%) at admission (visit 1).

### 282 **3.2 Time course of IL6 and SARS-CoV-2 viremia**

283 The average serum levels of IL6 and SARS-CoV-2 viral load were moderately but  
284 significantly correlated ( $r=0.41$ ,  $p=0.0014$ ; Supplementary Fig1).

285 Figure 1A shows the evolution over time of IL6 and viremia analyzed using data from the  
286 whole population (including IL6 after tocilizumab treatment). The peak of viremia appeared  
287 early, at the first days after symptom onset (day 3 to 5), and quickly decreased. On the other  
288 hand, the highest levels of IL6 were found at day 20. The wide 95% CI suggested a high  
289 heterogeneity, specially at both extremes of the time course. Figure 1B shows the results  
290 when the LOCF strategy (see Statistical section for further information) was used to  
291 minimize the increase of IL6 induced by tocilizumab (see supplementary Figure 2 for raw  
292 data in cases treated or not with tocilizumab). With LOCF strategy, the peak of IL6 was  
293 smaller, but the time course of IL6 production was quite similar to that obtained from raw

294 data. Hereinafter, the relationship between IL6 and SARS-CoV2 viral load shown  
295 corresponds to results obtained with the LOCF strategy.

296

### 297 **3.3 Relationship between IL6 and SARS-CoV-2 viremia**

298 A total of 19 patients had high IL6 (Table 1), of them 11 (57.9%) had persistent viremia  
299 compared to 5 patients (13.2%) in the low IL6 group ( $p=0.001$ ), with an odds ratio of 9.1  
300 (95%CI 2.5-32.6) (Figure 2E). In the graphic representation of IL6 and viral load according  
301 to high/low IL6 (Figure 2A, B), an early and minor peak of IL6 was found in the low IL6  
302 group, together with a small peak of viremia at day 4. On the other hand, patients with at least  
303 one IL6 above 30 pg/ml had an early high viremia around day 3 and a progressive increase of  
304 IL6 especially after day 12.

305 When the prediction of IL6 and viral load was calculated according to persistent viremia  
306 status, remarkable differences were obtained (Figure 2C, D). In the persistent viremia group,  
307 viral load showed a peak around day 4, whereas IL6 had a two-phase increase: one at the first  
308 days from symptom onset and then a subsequent progressive increase after day 5. Regarding  
309 non-persistent viremia the increase of IL6 was slow from symptom onset until day 20. The  
310 median of the average levels of IL6 were 3.6 pg/ml (IQR 1.0-9.2 pg/ml) in the non-persistent  
311 viremia group and 21.4 pg/ml (IQR 12.3-44.9) in patients with persistent viremia ( $p<0.001$ ).

### 312 **3.4 Prediction of IL6 and SARS-CoV-2 viremia according to demographic factors**

313 The effect of demographic factors on IL6 levels and SARS-CoV-2 viremia was also assessed.  
314 The median of the average IL6 concentration was significantly higher in males (11.3 pg/ml  
315 [IQR 3.3-27.5] than in females (2.5 pg/ml [IQR 0.7-9.2 pg/ml];  $p=0.005$ ). In the group of  
316 patients with high IL6, 84.2% were male compared to 50% in the group with low IL6  
317 ( $p=0.02$ ). No differences were found in the average viral load (11.1 copies/ml [IQR 0-197.3  
318 copies/ml] vs 2.3 copies/ml [IQR 0-6.8 copies/ml];  $p=0.08$ ) or in the percentage of patients  
319 with persistent viremia (34.3% vs 18.2%;  $p=0.24$ ) between males and females, respectively.  
320 However, predicting curves for IL6 and viral load were substantially different depending on  
321 sex (Figure 3A). In males, curves had a fast increase in viral load with a peak around day 2  
322 from symptom onset and a later rise in IL6 levels until day 20, while women showed a small  
323 increase in viral load and IL6 between day 2 and 7 approximately.

324 The effect of age on IL6 levels and viral load was also considered. The average levels of IL6  
325 and viremia did not correlate with age ( $r=0.21$ ,  $p=0.13$ ; and  $r=0.19$ ,  $p=0.16$ ; respectively).  
326 Moreover, no differences were found when age was categorized as <75 years and >75 years  
327 ( $p=0.57$  and  $p=0.88$ , for IL6 and viral load respectively). In the group with high IL6, 31.6%  
328 of patients were older than 75 years, the same percentage as in the low IL6 group ( $p=1$ ).  
329 Regarding persistent viremia, the proportion of patients older than 75 years was 29.3 % the  
330 group with non-persistent viremia and 37.5% in those with persistent viremia ( $p=0.55$ ). In the  
331 prediction curves according to age and sex, all parameters increased with age except for viral  
332 load in males, which peaked between 40 and 50 years (Figure 3B).

333 Regarding ethnicity, there were only differences between caucasians and latin-americans in  
334 the average IL6 levels (11.9 [IQR 2.9-35.2] vs 2.9 [IQR 1.0-4.3];  $p= 0.005$ ), and the  
335 percentage of patients with high IL6 (89.5% vs 5.3%,  $p=0.01$ ) (Table 1). No differences were  
336 found depending on ethnicity in the average viral load or the percentage of patients with  
337 persistent viremia.

338 Finally, a multivariable analysis showed that the presence of high IL6 was associated with  
339 persistent viremia (OR 10.0 [95%CI 2.0-49.5];  $p=0.005$ ); conversely, female sex (OR 0.17

340 [0.03-0.9];  $p=0.04$ ) and latin-american origin (OR 0.06 [0.01-0.7];  $p=0.02$ ) had a protective  
341 effect.

#### 342 **4 Discussion**

343 This study assessed the relationship between IL6 and SARS-CoV-2 viremia. The most  
344 relevant finding was the different time course of IL6 and viremia: the peak of viremia  
345 appeared shortly after symptom onset in patients with persistent viremia and also in those  
346 with at least one measure of  $IL6 > 30$  pg/ml, in which it was followed days later by a  
347 progressive increase in IL6. Moreover, the presence of persistent viremia in the first week of  
348 hospitalization was associated with higher levels of IL6. Both IL6 and SARS-CoV-2 viral  
349 load were higher in males, with a progressive increase with age that occurred earlier in males.

350  
351 Our findings are consistent with the COVID-19 phases first described by Siddiqui and Mehra  
352 [2]. These authors described an early stage characterized by a viral response (SARS-CoV-2  
353 viremia) and a final stage caused by a hyperinflammatory state characterized by increased  
354 levels of IL6. To date, the only study that has evaluated the kinetics of SARS-CoV-2 viremia  
355 and systemic cytokines, found that the levels of IL6 were associated with critical disease but  
356 not with the presence of viremia. However, only 20 patients were included in this study and  
357 the authors did not consider the different time course of the increase in viremia and IL6 [19].  
358 In our previous work [10], we described that the presence of relevant SARS-CoV-2 viremia  
359 was associated with higher risk of death and ICU admission. Furthermore, viremia was the  
360 most useful biomarker for these outcomes, being superior to IL6, lymphopenia and LDH. In  
361 the present study, we show that the SARS-CoV-2 viremia appears early in the course of the  
362 disease, standing out as a relevant, simple and early biomarker.

363  
364 Since the beginning of the pandemic, CRP and IL6 levels have not only been used as  
365 prognostic biomarkers in COVID-19 but also to guide treatment and predict response to  
366 tocilizumab [8,17,20]. However, Ong et al. and Liu et al. [21,22] showed that IL6 in COVID-  
367 19 patients peaked after the worsening of respiratory function, suggesting that when  
368 proinflammatory biomarkers rise, lung damage might be already established. In our cohort,  
369 68.8% of patients with persistent viremia had at least one  $IL6 > 30$  pg/ml in the later  
370 hyperinflammatory phase of the disease. Taking into account the high percentage of patients  
371 with persistent viremia who develop an hyperinflammatory response, these patients might be  
372 considered as candidates for intensive treatment and surveillance, or even for early treatment  
373 with IL6 blockade.

374  
375 Nevertheless, these findings might not be extensive to all patients. A more severe course of  
376 COVID-19 and higher levels of IL6 have been previously described in older males [23]. In  
377 this sense, genetic and hormonal factors have been proposed to be involved in age and sex  
378 related differences in COVID-19 [23,24]. One of the most studied SARS-CoV-2 related  
379 proteins is ACE2, the membrane receptor needed for the virus internalization, which is  
380 encoded by the gen of the same name located in the X chromosome [24,25]. ACE2  
381 expression increases with age and in male sex in COVID-19 patients [26,27]. ACE2  
382 expression also correlates with SARS-CoV-2 infectivity in cells of the respiratory tract [28]  
383 and with higher viral loads in nasopharyngeal swabs [29]. Whether endothelial and vascular  
384 ACE2 is related to viral load in peripheral blood has not been assessed yet, but it is plausible  
385 that higher levels of systemic ACE2 lead to increased viremia. Another proposed mechanism  
386 to explain sex differences is the effect of Toll Like Receptor (TLR) pathways, especially  
387 TLR7. This receptor, which recognizes viral single strain RNA and enhances IL6 production,  
388 is also located in X chromosome. TLR7 was one of the most important susceptibility genes

389 found in an Italian cohort of COVID-19 patients, where 6.3% of young males with life-  
390 threatening disease presented missense variants of this gene[30].

391

392 Regarding ethnicity, patients with a latinamerican origin had lower levels of IL6 in our  
393 cohort. In this sense, other cytokines and chemokines such as MCP-1, IL-10, IL-15, CXCL10  
394 and CCL2 have been associated with SARS-CoV-2 viremia [12,19]. It is possible that the  
395 immune response of latinamerican patients is enhanced by molecular pathways different from  
396 IL6, but this hypothesis needs to be further evaluated with studies with bigger sample size of  
397 our cohort.

398

399 This study has several limitations. First of all, the sample size of our cohort was small,  
400 although it was sufficient to find different patterns in the kinetics of IL6 and viral load.  
401 Secondly, all patients included were hospitalized and their first sample was obtained at a  
402 median of 7 days after symptom onset, therefore, data from the first days of the disease were  
403 limited. In addition, information about different variants of SARS-CoV-2 in our cohort could  
404 not be obtained because viral sequencing was not available in our facilities. However, at the  
405 time our study was performed, the most prevalent variant in Madrid was the original strain  
406 [31].

407

408 In conclusion, in those patients with worse outcomes, an early peak of SARS-CoV-2 viral  
409 load precedes around 5-10 days a prominent increase in IL6 levels. This finding was very  
410 clear in males older than 40 years. Therefore, monitoring SARS-CoV-2 viral load during the  
411 first week after symptom onset may be helpful to stratify the severity of patients and predict  
412 those who are at high risk of developing hyperinflammatory syndrome and ARDS.

413

## 414 **5 Conflict of Interest**

415

416 The authors declare that the research was conducted in the absence of any commercial or  
417 financial relationships that could be construed as a potential conflict of interest.

## 418 **6 Author Contributions**

419

420 ER-V, LC, IG-A and DAR-S designed the study and wrote the first draft of the manuscript;  
421 MCL, EA, AB, JH, JO, SCR-G, MC, CM, EGC, BG, RM, II, AV, AS-A, DA, JAR, PP, MT,  
422 MU, JMG-R, RG-V, JA, RdC and CSF included patients in the study and collected data; BQ,  
423 CAR, CM-C and EFR extracted and processed samples; ER-V, AT-M, NZ and LFG-R  
424 performed laboratory determinations; ER-V, AS and IG-A analyzed data; all authors  
425 reviewed the final draft.

## 426 **7 Funding**

427 This study was funded with grants: “Fondos Supera COVID19” by Banco Santander and  
428 CRUE to CS, RG-V, CM and JA; RD16/0011/0012 and PI18/0371 to IGA, from Ministerio  
429 de Economía y Competitividad (Instituto de Salud Carlos III) and co-funded by European  
430 regional development fund (ERDF) "A way to make Europe"; and co-financed by the  
431 Community of Madrid through the Covid 2019 Aid. The work of ER-V has been funded by a  
432 Rio-Hortega grant CM19/00149 from the Ministerio de Economía y Competitividad (Instituto  
433 de Salud Carlos III) and co-funded by The European Regional Development Fund (ERDF)  
434 "A way to make Europe". SR-G was funded by the Spanish Rheumatology Foundation  
435 (grants for physicians-researchers 2018-2021). None of these sponsors have had any role in

436 study design; in the collection, analysis, and interpretation of data; in the writing of the  
437 report; and in the decision to submit the article for publication.

## 438 **8 Acknowledgments**

439 Special thanks to our patients and relatives for agreeing with the use of pseudonymized  
440 clinical data and surpluses of clinical samples to perform this study, and Manuel Gomez  
441 Gutierrez, PhD for his excellent editing assistance.

442 PREDINMUN-COVID group includes:

443 Internal Medicine-Infectious Diseases: Jesús Sanz<sup>1</sup>, Pedro Casado<sup>1</sup>, Ángela Gutiérrez<sup>1</sup>,  
444 Azucena Bautista<sup>1</sup>, Pilar Hernández<sup>1</sup>, Nuria Ruiz Giménez<sup>1</sup>, Berta Moyano<sup>1</sup>, Paloma Gil<sup>1</sup>,  
445 María Jesús Delgado<sup>1</sup>, Pedro Parra<sup>1</sup>, Beatriz Sánchez<sup>1</sup>, Carmen Sáez<sup>1</sup>, Marta Fernández  
446 Rico<sup>1</sup>.

447 Microbiology: Diego Domingo García<sup>2</sup>, Teresa Alarcón Caverro<sup>2</sup>, María Auxiliadora Semiglia  
448 Chong<sup>2</sup>, Ainhoa Gutiérrez Cobos<sup>2</sup>.

449 Rheumatology: Santos Castañeda<sup>3</sup>, Irene Llorente<sup>3</sup>, Eva G. Tomero<sup>3</sup>, Noelia García  
450 Castañeda<sup>3</sup>, Nuria Montes<sup>3</sup>.

451 Intensive Care Unit: Cristina Dominguez Peña<sup>4</sup>, David Jiménez Jiménez<sup>4</sup>, Pablo Villamayor<sup>4</sup>,  
452 Alfonso Canabal<sup>4</sup>.

453 Pneumology: Tamara Alonso<sup>5</sup>, Carolina Cisneros<sup>5</sup>, Claudia Valenzuela<sup>5</sup>, Francisco Javier  
454 García Pérez<sup>5</sup>, Rosa María Girón<sup>5</sup>, Javier Aspa<sup>5</sup>, Celeste Marcos<sup>5</sup>, M. del Perpetuo Socorro  
455 Churruca<sup>5</sup>, Enrique Zamora<sup>5</sup>, Adrián Martínez<sup>5</sup>, Mar Barrio Mayo<sup>5</sup>, Rosalina Henares Espi<sup>5</sup>.

456 Immunology: Francisco Sánchez-Madrid<sup>9</sup>, Enrique Martín Gayo<sup>9</sup>, Ildfonso Sánchez-  
457 Cerrillo<sup>9</sup>, Ana Marcos Jimenez<sup>9</sup>, Pedro Martínez-Fleta<sup>9</sup>, Celia López-Sanz<sup>9</sup>, Ligia Gabrie<sup>9</sup>,  
458 Luciana del Campo Guerola<sup>9</sup>, Reyes Tejedor<sup>9</sup>, Rosa Carracedo-Rodríguez.

459

460

461

462

463

464

465

466

467

468

## 469 9 References

470

- 471 1. Li X, Ma X. Acute respiratory failure in COVID-19: is it “typical” ARDS? *Crit Care*  
472 (2020) 24: 198. doi:10.1186/s13054-020-02911-9
- 473 2. Siddiqi HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States: A  
474 Clinical-Therapeutic Staging Proposal. *The Journal of Heart and Lung Transplantation*  
475 (2020) 39(5):405-407 doi:10.1016/j.healun.2020.03.012
- 476 3. Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of  
477 mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis.  
478 *J Med Virol* (2020) 92: 1875–1883. doi:10.1002/jmv.26050
- 479 4. Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors of  
480 COVID-19 severity: A literature review. *Rev Med Virol* (2021) 31: 1–10.  
481 doi:10.1002/rmv.2146
- 482 5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for  
483 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort  
484 study. *The Lancet* (2020) 395: 1054–1062. doi:10.1016/S0140-6736(20)30566-3
- 485 6. Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk Factors for Severe Disease and  
486 Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review,  
487 Meta-Analysis, and Meta-Regression Analysis. *Clinical Infectious Diseases* (2020) 71:  
488 2199–2206. doi:10.1093/cid/ciaa576
- 489 7. Mesas AE, Cavero-Redondo I, Álvarez-Bueno C, Sarriá Cabrera MA, Maffei de  
490 Andrade S, Sequí-Dominguez I, et al. Predictors of in-hospital COVID-19 mortality: A  
491 comprehensive systematic review and meta-analysis exploring differences by age, sex  
492 and health conditions. *PLoS ONE* (2020) 15: e0241742.  
493 doi:10.1371/journal.pone.0241742
- 494 8. Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E, Marcos-Jiménez A, Sánchez-  
495 Alonso S, Fernández-Díaz C, et al. IL-6 serum levels predict severity and response to  
496 Tocilizumab in COVID-19: an observational study. *Journal of Allergy and Clinical*  
497 *Immunology* (2020) 147(1):72-80.e8. doi:10.1016/j.jaci.2020.09.018
- 498 9. Tang K, Wu L, Luo Y, Gong B. Quantitative assessment of SARS-CoV-2 RNAemia  
499 and outcome in patients with coronavirus disease 2019. *J Med Virol* (2021) 93: 3165–  
500 3175. doi:10.1002/jmv.26876
- 501 10. Rodríguez-Serrano DA, Roy-Vallejo E, Zurita Cruz ND, Martín Ramírez A, Rodríguez-  
502 García SC, Arevalillo-Fernández N, et al. Detection of SARS-CoV-2 RNA in serum is  
503 associated with increased mortality risk in hospitalized COVID-19 patients. *Sci Rep*  
504 (2021)11: 13134. doi:10.1038/s41598-021-92497-1
- 505 11. Saji R, Nishii M, Sakai K, Miyakawa K, Yamaoka Y, Ban T, et al. Combining IL-6 and  
506 SARS-CoV-2 RNAemia-based risk stratification for fatal outcomes of COVID-19.  
507 Lazzeri C, editor. *PLoS ONE* (2021) 16: e0256022. doi:10.1371/journal.pone.0256022
- 508 12. Bermejo-Martin JF, González-Rivera M, Almansa R, Micheloud D, Tedim AP,  
509 Domínguez-Gil M, et al. Viral RNA load in plasma is associated with critical illness and  
510 a dysregulated host response in COVID-19. *Critical Care* (2020) 24: 691.  
511 doi:10.1186/s13054-020-03398-0
- 512 13. Myhre PL, Prebensen C, Jonassen CM, Berdal JE, Omland T. SARS-CoV-2 Viremia  
513 is Associated With Inflammatory, But Not Cardiovascular Biomarkers, in Patients  
514 Hospitalized for COVID-19. *JAHA* (2021) 10(9):e019756.  
515 doi:10.1161/JAHA.120.019756
- 516 14. Li Y, Schneider AM, Mehta A, Sade-Feldman M, Kays KR, Gentili M, et al. SARS-  
517 CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19  
518 outcomes. *Journal of Clinical Investigation* (2021) 131(13):e148635.  
519 doi:10.1172/JCI148635

- 520 15. Martín Ramírez A, Zurita Cruz ND, Gutiérrez-Cobos A, Rodríguez Serrano DA,  
521 González Álvaro I, Roy Vallejo E, et al. Evaluation of two RT-PCR techniques for  
522 SARS-CoV-2 RNA detection in serum for microbiological diagnosis. *Journal of*  
523 *Virological Methods* (2022) 300: 114411. doi:10.1016/j.jviromet.2021.114411
- 524 16. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and  
525 pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6  
526 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients  
527 with rheumatoid arthritis and Castleman disease. *Blood* (2008) 112: 3959–3964.  
528 doi:10.1182/blood-2008-05-155846
- 529 17. The Spanish Agency for Medicine and Health Products - [Agencia Española de  
530 Medicamentos y Productos Sanitarios (AEMPS)]. Treatments available for the  
531 management of respiratory infection by SARS-CoV-2 - [Tratamientos disponibles para  
532 el manejo de la infección respiratoria por SARS-CoV-2]. Apr 2020 [cited 11 Jan 2022].  
533 Available: [https://www.aemps.gob.es/laAEMPS/docs/medicamentos-disponibles-](https://www.aemps.gob.es/laAEMPS/docs/medicamentos-disponibles-SARS-CoV-2-16-4-2020.pdf)  
534 [SARS-CoV-2-16-4-2020.pdf](https://www.aemps.gob.es/laAEMPS/docs/medicamentos-disponibles-SARS-CoV-2-16-4-2020.pdf)
- 535 18. World Health Organization. WHO R&D Blueprint. Novel Coronavirus COVID-19  
536 Therapeutic Trial Synopsis. 2020 [cited 11 Jan 2022]. Available:  
537 [https://www.who.int/blueprint/priority-diseases/key-action/COVID-](https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf)  
538 [19\\_Treatment\\_Trial\\_Design\\_Master\\_Protocol\\_synopsis\\_Final\\_18022020.pdf](https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf)
- 539 19. van Riel D, Embregts CWE, Sips GJ, van den Akker JPC, Endeman H, van Nood E, et  
540 al. Temporal Kinetics of RNAemia and Associated Systemic Cytokines in Hospitalized  
541 COVID-19 Patients. Frieman MB, editor. *mSphere* (2021) 30;6(3):e0031121.  
542 doi:10.1128/mSphere.00311-21
- 543 20. Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al. Tocilizumab in  
544 patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled,  
545 open-label, platform trial. *The Lancet* (2021) 397: 1637–1645. doi:10.1016/S0140-  
546 6736(21)00676-0
- 547 21. Liu Z, Li J, Chen D, Gao R, Zeng W, Chen S, et al. Dynamic Interleukin-6 Level  
548 Changes as a Prognostic Indicator in Patients With COVID-19. *Front Pharmacol* (2020)  
549 11: 1093. doi:10.3389/fphar.2020.01093
- 550 22. Ong EZ, Chan YFZ, Leong WY, Lee NMY, Kalimuddin S, Haja Mohideen SM, et al.  
551 A Dynamic Immune Response Shapes COVID-19 Progression. *Cell Host & Microbe*  
552 (2020) 27: 879-882.e2. doi:10.1016/j.chom.2020.03.021
- 553 23. Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-  
554 aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes.  
555 *Cytokine & Growth Factor Reviews* (2020) 53: 33–37.  
556 doi:10.1016/j.cytogfr.2020.04.005
- 557 24. Rehman S, Ravinayagam V, Nahvi I, Aldossary H, Al-Shammari M, Amiri MSA, et al.  
558 Immunity, Sex Hormones, and Environmental Factors as Determinants of COVID-19  
559 Disparity in Women. *Front Immunol* (2021) 12: 680845.  
560 doi:10.3389/fimmu.2021.680845
- 561 25. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2  
562 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic  
563 target. *Intensive Care Med* (2020) 46: 586–590. doi:10.1007/s00134-020-05985-9
- 564 26. Peng J, Sun J, Zhao J, Deng X, Guo F, Chen L. Age and gender differences in ACE2  
565 and TMPRSS2 expressions in oral epithelial cells. *J Transl Med* (2021) 19: 358.  
566 doi:10.1186/s12967-021-03037-4
- 567 27. Sward P, Edsfeldt A, Reepalu A, Jehpsson L, Rosengren BE, Karlsson MK. Age and  
568 sex differences in soluble ACE2 may give insights for COVID-19. *Crit Care* (2020) 24:  
569 221. doi:10.1186/s13054-020-02942-2
- 570 28. Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH, et al. SARS-

571 CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract.  
572 Cell (2020) 182: 429-446.e14. doi:10.1016/j.cell.2020.05.042  
573 29. Lieberman NAP, Peddu V, Xie H, Shrestha L, Huang M-L, Mears MC, et al. In vivo  
574 antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age.  
575 Cadwell K, editor. PLoS Biol (2020) 18: e3000849. doi:10.1371/journal.pbio.3000849  
576 30. Fallerini C, Daga S, Mantovani S, Benetti E, Picchiotti N, Francisci D, et al. Association  
577 of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males:  
578 findings from a nested case-control study. Elife.(2021) 10:e67569. doi:  
579 10.7554/eLife.67569  
580 31. Dirección General de Salud Pública de la Comunidad de Madrid. Informe semanal de  
581 Vigilancia Epidemiológica de la COVID-19. 2021 2020 [cited 19 Dec 2021]. Available:  
582 <https://www.comunidad.madrid/servicios/salud/coronavirus>  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621

622

623 **10 Tables**

624

625 Table 1. Baseline clinical characteristics of the study population according to IL6 levels.

626

	Study population (n=57)	Low IL6 (n=38)	High IL6 (n=19)	p value
Age; median (IQR)	63 (53-81)	60 (49-81)	72 (59-81)	0.21
Male sex; n (%)	35 (61.4)	19 (50)	16 (84.2)	0.02
Race/ethnicity; n (%)				0.009
-Caucasian	39 (68.4)	22 (57.9)	17 (89.4)	*0.01
-Latin-american	16 (28.1)	15 (39.5)	1 (5.3)	
-Asian	2 (3.5)	1 (2.6)	1 (5.3)	
Comorbidities; n (%)	43 (75.4)	30 (79)	13 (68.4)	0.5
Age-adjusted Charlson's Comorbidity Index; median (IQR)	3 (1-5)	2.5 (1-5)	4 (1-5)	0.37
Days from symptom onset to first sample; median (IQR)	8 (4-10)	8 (4-12)	6 (3-8)	0.12
Persistent viremia; n (%)	16 (28.1)	5 (13.2)	11 (57.9)	0.001
Clinical progression <sup>^</sup> ; n (%)	12 (21.1)	3 (7.9)	9 (47.4)	0.001
Intensive Care Unit; n (%)	8 (14)	3 (7.9)	5 (26.3)	0.1
In-hospital mortality; n(%)	5 (8.8)	0	5 (26.3)	0.003

627 \* Significant differences were only found between caucasians and latin-americans. <sup>^</sup>Clinical  
 628 progression was defined as a worsening of at least one point on the WHO COVID Ordinal  
 629 Outcomes Scale [18] during a 14-day follow-up after admission.

630

631

632

633

634

## 635 **11 Figure Legends**

636

637

638 Figure 1. The peak of viral load precedes the IL6 increase. Graphic representation of time-  
639 course of IL6 levels and SARS-CoV-2 viral load from symptom onset. Panel (A)  
640 representation of raw data. Panel (B) Representation of data after applying the LOCF  
641 strategy. The fractional polynomial prediction was performed using the *twoway* command of  
642 Stata.

643

644

645 Figure 2. Patients with worse outcomes have an early peak of SARS-CoV-2 viral load before  
646 a prominent increase in IL6 levels. Graphic representation of IL6 levels and SARS-CoV-2  
647 viral load from symptom onset in: (A) patients with low IL6; (B) patients with at least one  
648 IL6>30 pg/ml (high IL6); (C) non-persistent viremia and (D) persistent viremia. Panel (E)  
649 represents the percentage of patients with persistent viremia according to IL6 levels (low  
650 versus high). Panels (A) to (D), the fractional polynomial predictions were performed using  
651 the *twoway* command of Stata.

652

653



654 Figure 3. Males had more relevant increases of IL6 and viral load. Panel (A) represents the  
655 levels of IL6 and viral load from symptom onset by sex, while panel (B) shows levels of IL6  
656 and viral load by age and sex. The fractional polynomial predictions were performed using  
657 the *twoway* command of Stata.

658

659

660

A)



B)

